Approved in Europe, tabelecleucel may soon be considered by FDA to treat patients who develop Epstein-Barr virus following a transplant, which then triggers a type of deadly lymphoma that may not respond to traditional therapy. Tab-cel, an allogeneic T-cell therapy, comes 30 years after the discovery that T cells might offer hope, followed by decades of research on how to harness them without the side effects.
ATARA Biotherapeutics (ATRA) and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel Data streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel® Data in The Lancet Oncology streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.